Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:CYTK NASDAQ:GMAB NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$195.54-0.2%$174.44$111.09▼$199.99$11.95B0.41493,716 shs265,528 shsCYTKCytokinetics$34.59+4.1%$34.92$29.31▼$59.39$4.14B0.641.74 million shs602,327 shsGMABGenmab A/S$21.75+3.2%$21.73$17.24▼$27.94$13.95B0.951.45 million shs561,192 shsRDYDr. Reddy's Laboratories$13.89+0.5%$14.83$12.26▼$16.85$11.59B0.291.88 million shs341,313 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+2.34%+6.42%+12.01%+21.33%+54.34%CYTKCytokinetics-2.58%-9.16%-10.21%+8.56%-40.44%GMABGenmab A/S-1.63%-4.09%-1.50%+9.17%-20.24%RDYDr. Reddy's Laboratories-0.07%+0.07%-4.86%-1.95%-17.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S2.6812 of 5 stars3.52.00.00.03.31.70.6CYTKCytokinetics4.2152 of 5 stars4.41.00.04.63.70.80.0GMABGenmab A/S3.7116 of 5 stars3.33.00.00.03.90.03.1RDYDr. Reddy's Laboratories2.5591 of 5 stars2.52.01.70.03.30.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$239.8022.63% UpsideCYTKCytokinetics 2.88Moderate Buy$70.69104.38% UpsideGMABGenmab A/S 2.64Moderate Buy$37.8073.83% UpsideRDYDr. Reddy's Laboratories 3.00Buy$16.9522.07% UpsideCurrent Analyst Ratings BreakdownLatest CYTK, GMAB, RDY, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025ASNDAscendis Pharma A/SCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025ASNDAscendis Pharma A/SWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$289.00 ➝ $295.008/8/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$243.00 ➝ $290.008/8/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$210.00 ➝ $230.008/8/2025ASNDAscendis Pharma A/SUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$306.00 ➝ $307.008/8/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$212.00 ➝ $220.008/8/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $203.008/8/2025ASNDAscendis Pharma A/SStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$212.00 ➝ $254.008/8/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $77.007/30/2025CYTKCytokineticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform7/29/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$245.00 ➝ $254.00(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M30.38N/AN/A($1.88) per share-104.01CYTKCytokinetics$18.47M224.09N/AN/A($1.15) per share-30.08GMABGenmab A/S$3.12B4.47$1.54 per share14.13$8.04 per share2.70RDYDr. Reddy's Laboratories$3.81B3.04$1.04 per share13.36$4.73 per share2.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A814.75N/A-54.94%N/A-24.31%N/ACYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%N/AGMABGenmab A/S$1.14B$1.9910.9312.226.3537.53%21.03%16.98%N/ARDYDr. Reddy's Laboratories$663M$0.6621.0416.935.5216.99%17.25%11.63%N/ALatest CYTK, GMAB, RDY, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.50%N/A10.61%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69CYTKCytokineticsN/A6.766.76GMABGenmab A/SN/A6.226.20RDYDr. Reddy's Laboratories0.011.891.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ACYTKCytokineticsN/AGMABGenmab A/S7.07%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%CYTKCytokinetics3.40%GMABGenmab A/S1.54%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.15 million36.69 millionOptionableCYTKCytokinetics250119.66 million115.59 millionOptionableGMABGenmab A/S2,682641.54 million631.66 millionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableCYTK, GMAB, RDY, and ASND HeadlinesRecent News About These CompaniesCritical Review: Dr. Reddy's Laboratories (NYSE:RDY) vs. Targeted Medical Pharma (OTCMKTS:TRGM)August 11 at 2:13 AM | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) vs. Aspen Pharmacare (OTCMKTS:APNHY) Head-To-Head SurveyAugust 10 at 2:08 AM | americanbankingnews.comXY Capital Ltd Sells 47,520 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 9 at 6:47 AM | marketbeat.comUS Bancorp DE Has $2.15 Million Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 9 at 3:47 AM | marketbeat.comPinpoint Asset Management Ltd Reduces Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 8, 2025 | marketbeat.comEnvestnet Asset Management Inc. Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 7, 2025 | marketbeat.comDr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New RevenuesAugust 4, 2025 | seekingalpha.comComparing Dr. Reddy's Laboratories (NYSE:RDY) and Acura Pharmaceuticals (OTCMKTS:ACUR)August 2, 2025 | americanbankingnews.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Allianz Asset Management GmbHJuly 29, 2025 | marketbeat.comDr. Reddy’s Laboratories Releases Q1 2025 Earnings Call AudioJuly 25, 2025 | theglobeandmail.comDr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost RevenuesJuly 24, 2025 | zacks.comDr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call TranscriptJuly 23, 2025 | seekingalpha.comDr. Reddy's Laboratories Limited 2026 Q1 - Results - Earnings Call PresentationJuly 23, 2025 | seekingalpha.comDr. Reddy's Q1FY26 Financial ResultsJuly 23, 2025 | businesswire.comDr. Reddy’s to launch generic semaglutide in 87 countries: BloombergJuly 23, 2025 | msn.comDr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License AgreementJuly 23, 2025 | msn.comCerity Partners LLC Buys 88,628 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 20, 2025 | marketbeat.comCenterBook Partners LP Makes New Investment in Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 19, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Migdal Insurance & Financial Holdings Ltd.July 19, 2025 | marketbeat.comNew Strong Sell Stocks for July 18thJuly 18, 2025 | zacks.comDr. Reddy's Laboratories (RDY) Expected to Announce Earnings on FridayJuly 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTK, GMAB, RDY, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$195.54 -0.43 (-0.22%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Cytokinetics NASDAQ:CYTK$34.59 +1.36 (+4.09%) As of 01:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Genmab A/S NASDAQ:GMAB$21.74 +0.67 (+3.15%) As of 01:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Dr. Reddy's Laboratories NYSE:RDY$13.88 +0.07 (+0.47%) As of 01:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces Alphabet Reclaims $200 Threshold—Bull Run Reignited? How Vertiv Is Cashing in on AI's Power Crisis CrowdStrike Faces Valuation Test Before Key Earnings Report AMD Paves Path for Market Share Gains: Stock Rally Has Just Begun Post-Earnings, How Does D-Wave Stack Up Against Quantum Rivals? MNDY Stock Has a Case of the Mondays—Buy Before the Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access